1937

524518

KREBSBIO

img img img img
No Data Available

KREBS BIOCHEMICALS & IND Share Price Update

As of the latest trading session, KREBS BIOCHEMICALS & IND share price is currently at ₹59.8, which is up by ₹0.30 from its previous closing. Today, the stock has fluctuated between ₹59.00 and ₹61.28. Over the past year, KREBS BIOCHEMICALS & IND has achieved a return of -30.00%. In the last month alone, the return has been -6.28%.

KREBS BIOCHEMICALS & IND performance

Today’s low

Today’s high

₹ 59.00 ₹ 61.28
₹ 59.80

52 week low

52 week high

₹ 53.05 ₹ 113.50
₹ 59.80

Open Price

₹ 59.12

Prev. Close

₹ 59.49

Volume (Shares)

3795.00

Total traded value

₹ 2.26

Upper Circuit

₹ 71.38

Lower Circuit

₹ 47.60

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

KREBS BIOCHEMICALS & IND fundamentals


  • Market cap (Cr)

    128.90

  • P/E Ratio (TTM)

    -5.61

  • Beta

    1.06

  • Book Value / share

    -74.59

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -3.13

info icon alternate text
  • Market cap (Cr)

    124.20

  • P/E Ratio (TTM)

    -5.61

  • Beta

    0.96

  • Book Value / share

    -74.59

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -3.13

info icon alternate text

KREBS BIOCHEMICALS & IND Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 7.27
Operating Expense 10.39
Net Profit -3.13
Net Profit Margin (%) -43.05
Earnings Per Share (EPS) -1.45
EBITDA 0.29
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 4.17
Operating Expense 10.31
Net Profit -6.14
Net Profit Margin (%) -147.24
Earnings Per Share (EPS) -2.85
EBITDA -2.79
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 5.48
Operating Expense 10.82
Net Profit -5.32
Net Profit Margin (%) -97.08
Earnings Per Share (EPS) -2.47
EBITDA -2.07
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 6.10
Operating Expense 14.69
Net Profit -8.27
Net Profit Margin (%) -135.57
Earnings Per Share (EPS) -3.83
EBITDA -5.06
Effective Tax Rate (%) -0.24
Particulars DEC 2024 (Values in Cr)
Revenue 11.47
Operating Expense 19.45
Net Profit -7.74
Net Profit Margin (%) -67.48
Earnings Per Share (EPS) -3.59
EBITDA -4.46
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 43.31
Operating Expense 70.94
Net Profit -26.94
Net Profit Margin (%) -62.20
Earnings Per Share (EPS) -12.49
EBITDA -14.32
Effective Tax Rate (%) -0.07
Particulars MAR 2024 (Values in Cr)
Revenue 50.42
Operating Expense 70.60
Net Profit -19.73
Net Profit Margin (%) -39.13
Earnings Per Share (EPS) -9.16
EBITDA -8.27
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 52.13
Operating Expense 77.44
Net Profit -24.69
Net Profit Margin (%) -47.36
Earnings Per Share (EPS) -11.30
EBITDA -15.16
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 59.70
Operating Expense 105.38
Net Profit -44.53
Net Profit Margin (%) -74.58
Earnings Per Share (EPS) -20.81
EBITDA -32.84
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 38.61
Operating Expense 82.68
Net Profit -28.36
Net Profit Margin (%) -73.45
Earnings Per Share (EPS) -14.37
EBITDA -16.95
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share -67.83
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -33.06
Particulars MAR 2024 (Values in Cr)
Book Value / Share -55.29
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.83
EBITDA Margin -16.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share -46.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.78
EBITDA Margin -29.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share -34.83
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.23
EBITDA Margin -55.01
Particulars MAR 2021 (Values in Cr)
Book Value / Share -23.91
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -31.56
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 169.03
Total Liabilities 169.03
Total Equity -146.23
Share Outstanding 2
Price to Book Ratio -0.98
Return on Assets (%) -15.93
Return on Capital (%) -40.84
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.13
Total Assets 178.17
Total Liabilities 178.17
Total Equity -119.21
Share Outstanding 2
Price to Book Ratio -1.10
Return on Assets (%) -11.07
Return on Capital (%) -26.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.08
Total Assets 174.98
Total Liabilities 174.98
Total Equity -99.46
Share Outstanding 2
Price to Book Ratio -1.22
Return on Assets (%) -14.11
Return on Capital (%) -29.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 189.80
Total Liabilities 189.80
Total Equity -75.09
Share Outstanding 2
Price to Book Ratio -4.12
Return on Assets (%) -23.45
Return on Capital (%) -65.65
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.71
Total Assets 159.22
Total Liabilities 159.22
Total Equity -42.73
Share Outstanding 1
Price to Book Ratio -3.72
Return on Assets (%) -17.81
Return on Capital (%) -41.82
Particulars MAR 2025 (Values in Cr)
Net Income -26.92
Cash from Operations -7.87
Cash from Investing -4.96
Cash from Financing 12.86
Net change in Cash 0.00
Free Cash Flow -4.47
Particulars MAR 2024 (Values in Cr)
Net Income -19.72
Cash from Operations 2.36
Cash from Investing -7.81
Cash from Financing 5.50
Net change in Cash 0.05
Free Cash Flow 11.77
Particulars MAR 2023 (Values in Cr)
Net Income -24.69
Cash from Operations -24.71
Cash from Investing -12.64
Cash from Financing 37.34
Net change in Cash -0.01
Free Cash Flow -9.55
Particulars MAR 2022 (Values in Cr)
Net Income -44.52
Cash from Operations -17.21
Cash from Investing -22.89
Cash from Financing 39.50
Net change in Cash -0.61
Free Cash Flow 9.86
Particulars MAR 2021 (Values in Cr)
Net Income -28.35
Cash from Operations -14.57
Cash from Investing -22.54
Cash from Financing 37.66
Net change in Cash 0.53
Free Cash Flow 3.18
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.49 11.90 1.42 210.66 23.12 / 46.00
BLISS GVS PHARMA LTD 229.90 21.98 2.14 2432.09 105.05 / 244.05
CIPLA LTD 1349.10 22.92 3.31 108977.69 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 327.30 10.89 2.46 963.28 219.00 / 399.00
GLAXOSMITHKLINE PHARMA LT 2584.40 43.53 25.63 43781.30 2220.00 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.49 26.43 3.83 210.66 23.12 / 46.00
AMRUTAJAN HEALTH LTD 628.00 31.40 5.30 1815.59 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8888.85 106.82 27.81 22222.13 6501.60 / 10653.05
BLISS GVS PHARMA LTD 229.90 31.32 2.20 2432.09 105.05 / 244.05

KREBS BIOCHEMICALS & IND shareholding pattern

Holding

26.76%
72.74%
0.48%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

KREBS BIOCHEMICALS & IND Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
59.80 0.52 redarrow
red-green-graph indicator
9 Bearish
7 Bullish
  • 5 Days 58.80
  • 26 Days 60.10
  • 10 Days 58.60
  • 50 Days 62.60
  • 12 Days 58.60
  • 100 Days 66.30
  • 20 Days 59.40
  • 200 Days 70.90
59.30 PIVOT

First Support

57.99

First Resistance

60.79

Second Support

56.50

Second Resistance

62.10

Third Support

55.19

Third Resistance

63.59

RSI

47.95

ADX

45.10

MACD

-1.46

Williams % R

-37.61

Commodity Channel Index (CCI)

44.07

Date

2026-02-18

Week

3609.00

Same Day

1520.00

Month

8890.00

1 Year

1.07

3 Year

1.04

Over 1 Month

-6.28%

down

Over 1 Year

-30.00%

down

Over 3 Months

-11.36%

down

Over 3 Years

-11.64%

down

Over 6 Months

-21.91%

down

Over 5 Years

-11.55%

down

KREBS BIOCHEMICALS & IND Corporate Actions

Top Gainers

KREBS BIOCHEMICALS & IND Share Price

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991. The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003. Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same.

The Company develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies.

KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994.

During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process.

The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards.

Production of two new products has commenced in the Nellore unit of the company during 2008. The sales from Unit II showed a healthy increase and small activity started in Unit I through Contract Manufacturing in 2010-11. The steep drop in income was attributed to discontinuing of Lovastatin manufacturing from April, 2012 in Unit ll. Starting from April 2012, the power supply was restricted the Andhra Pradesh government making it unviable and impractical to run the manufacturing of Lovastatin. Further, this affected the manufacturing of Simvastatin for which Lovastatin as the key raw material. Unit 2 due to the power shortage became sick in 2012.

The Company undertook a financial restructuring to revive the operations in 2013. Ipca Laboratories Limited acquired 31.38% stake in the Company, making it an associate Company during FY15.

During the year 2015-16, complete repairs and maintenance of both plants were undertaken to make plants ready for operations after the long shutdown. Some modernisation works were undertaken to meet the latest pollution control norms and safety regulations. All relevant licences were renewed. All the pending statutory requirements were addressed. Products range for both plants was established. Scale up operations including technology sourcing/development, pilot plant trials and validation trails for the identified products began in 2016.

During the FY 2019-20, A total of four products were produced in its plant including Phenylephrine HCl, Simvastatin, Serratiopeptidase and RSS.

The Vizag manufacturing facility of the Company started manufacturing few drug intermediates in 2023. The manufacturing operations at the Company's Vizag manufacturing unit remained closed since 9th February 2025 pursuant to order issued by Andhra Pradesh Pollution Control Board.

Parent organization Indian Private
NSE symbol KREBSBIO
Founded 1991
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Krebs Biochemicals & Industries Ltd?

Answer Field

Krebs Biochemicals & Industries Ltd share price is for NSE ₹ 59.80 & for BSE ₹ 0.00 as on Feb 19 2026 03:29 PM.

What is the Market Cap of Krebs Biochemicals & Industries Ltd Share?

Answer Field

The market cap of Krebs Biochemicals & Industries Ltd for NSE ₹ 128.90 & for BSE ₹ 0.00 as on Feb 19 2026 03:29 PM.

What is the 52 Week High and Low of Krebs Biochemicals & Industries Ltd?

Answer Field

The 52 Week High and Low of Krebs Biochemicals & Industries Ltd for NSE is ₹ 113.50 and ₹ 53.05 and for BSE is ₹ 113.90 and ₹ 51.00.

What is 1 year return for Krebs Biochemicals & Industries Ltd?

Answer Field

The 1 year returns on the stock has been -30.00%.

What is the P/E Ratio of Krebs Biochemicals & Industries Ltd Share?

Answer Field

As on Feb 19 2026 03:29 PM the price-to-earnings (PE) ratio for Krebs Biochemicals & Industries Ltd share is -5.61.

What is the PB ratio of Krebs Biochemicals & Industries Ltd Share?

Answer Field

As on Feb 19 2026 03:29 PM, the price-to-book (PB) ratio for Krebs Biochemicals & Industries Ltd share is -74.59.

How to Buy Krebs Biochemicals & Industries Ltd Share?

Answer Field

You can trade in Krebs Biochemicals & Industries Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Krebs Biochemicals & Industries Ltd Share on Bajaj Broking App?

Answer Field

To buy Krebs Biochemicals & Industries Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Krebs Biochemicals & Industries Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59